Qualit-E-SpeakPharma-Insert
X

Find drug development pipeline and deal Updates information

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Oxy210

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 03, 2020

            Details:

            Oxy210 was found to significantly inhibit development of fibrosis in a humanized mouse model of NASH that involves progressive inflammation, fat deposition and fibrosis in the livers of these mice.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CRV431

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 19, 2020

            Details:

            In vitro studies showed that CRV431 can decrease production of the extracellular matrix molecules, collagen and fibronectin, from fibroblastic cells derived from five different organs.